Get the Stockscreener App
1.80
2.86%
0.05
Aclaris Therapeutics Inc stock is traded at $1.80, with a volume of 577.10K.
It is up +2.86% in the last 24 hours and up +11.11% over the past month.
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two reportable segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases, and the contract research segment is engaged in providing laboratory services. A majority of the company's revenue is derived from the therapeutics segment. The various drug candidates in its product pipeline are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138, an ITJ Inhibitor; Bosakitug, ATI-052, and Lepzacitinib.
See More
Previous Close:
$1.75
Open:
$1.76
24h Volume:
577.10K
Relative Volume:
0.52
Market Cap:
$195.00M
Revenue:
$27.08M
Net Income/Loss:
$-37.00M
P/E Ratio:
-3.4615
EPS:
-0.52
Net Cash Flow:
$-18.46M
1W Performance:
-3.74%
1M Performance:
+11.11%
6M Performance:
-19.64%
1Y Performance:
+50.00%
1-Day Range:
$1.755
$1.8272
1-Week Range:
$1.745
$1.92
52-Week Range:
$1.05
$5.17
Aclaris Therapeutics Inc Stock (ACRS) Company Profile
Name
Aclaris Therapeutics Inc
Sector
Industry
Phone
484-324-7933
Address
701 LEE ROAD, WAYNE, PA
Compare ACRS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ACRS
Aclaris Therapeutics Inc
|
1.80 | 200.41M | 27.08M | -37.00M | -18.46M | -0.52 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.12 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
589.48 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.38 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
660.00 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
313.67 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Aclaris Therapeutics Inc Stock (ACRS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-10-25 | Resumed | Piper Sandler | Overweight |
| May-28-25 | Initiated | Wedbush | Outperform |
| Mar-18-25 | Resumed | Cantor Fitzgerald | Overweight |
| Dec-23-24 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Nov-20-24 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Nov-19-24 | Upgrade | BTIG Research | Neutral → Buy |
| Nov-19-24 | Upgrade | Jefferies | Hold → Buy |
| Nov-19-24 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Nov-18-24 | Upgrade | Piper Sandler | Neutral → Overweight |
| Jan-22-24 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Nov-13-23 | Downgrade | William Blair | Outperform → Mkt Perform |
| Oct-03-23 | Initiated | Evercore ISI | Outperform |
| Dec-14-22 | Initiated | Stifel | Buy |
| Dec-01-22 | Initiated | Goldman | Buy |
| Oct-06-22 | Initiated | BTIG Research | Buy |
| Jul-23-21 | Resumed | Jefferies | Buy |
| Jun-15-21 | Initiated | Piper Sandler | Overweight |
| Apr-21-21 | Initiated | H.C. Wainwright | Buy |
| Oct-22-19 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Sep-06-19 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| Jun-27-19 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| May-06-19 | Initiated | SVB Leerink | Outperform |
| Mar-28-18 | Resumed | Leerink Partners | Outperform |
| Feb-09-18 | Initiated | Guggenheim | Buy |
| Jun-16-17 | Initiated | Cantor Fitzgerald | Overweight |
| Nov-29-16 | Initiated | Leerink Partners | Outperform |
| Sep-30-16 | Initiated | JMP Securities | Mkt Outperform |
| Jun-10-16 | Initiated | Guggenheim | Buy |
| Nov-02-15 | Initiated | Citigroup | Buy |
| Nov-02-15 | Initiated | Jefferies | Buy |
View All
Aclaris Therapeutics Inc Stock (ACRS) Latest News
Aclaris Therapeutics Reports Q1 2025 Results and Pipeline Updates - MSN
Can Aclaris Therapeutics Inc. recover in the next quarterJuly 2025 Price Swings & Free Weekly Chart Analysis and Trade Guides - Newser
Price Reversal in Aclaris Therapeutics Inc. Traders Watch CloselyPortfolio Return Summary & Consistent Profit Trade Alerts - beatles.ru
Aclaris Therapeutics Reports Positive Phase 2a Clinical Trial Results for ATI-2138 - Yahoo Finance
13 Most Promising Penny Stocks Under $5 - Insider Monkey
Aclaris Reports Positive Phase 2a Results for ATI-2138 in Atopic Dermatitis Trial - MSN
Will Aclaris Therapeutics Inc. Reverse From Oversold Conditions2025 Growth vs Value & Community Supported Trade Ideas - newsyoung.net
Aclaris Therapeutics Taps Veteran Biotech Leader Roland Kolbeck as New Chief Scientific Officer - MSN
Aclaris Therapeutics Reports Q2 Loss, Highlights Progress in Immuno-Dermatology Pipeline - MSN
Will Aclaris Therapeutics Inc. outperform the marketPortfolio Risk Summary & Stock Market Timing Techniques - Newser
Aclaris Therapeutics Inc. Moves Into Overbought Range Analysts Cautious2025 Sector Review & Weekly High Potential Stock Alerts - 선데이타임즈
Can trapped investors hope for a rebound in Aclaris Therapeutics Inc.Rate Hike & AI Driven Stock Reports - Newser
Combining machine learning predictions for Aclaris Therapeutics Inc.Weekly Profit Summary & Real-Time Buy Signal Alerts - Newser
Aclaris Therapeutics Inc. stock trend outlook and recovery pathQuarterly Profit Summary & Real-Time Stock Movement Alerts - Newser
How Efficient Is Aclaris Therapeutics Inc. at Controlling Operating CostsPortfolio Building Plan and Summary Guide - Newser
Market reaction to Aclaris Therapeutics Inc.’s recent newsCapital Growth Summary Over Five Years - Newser
Earnings Update: Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Just Reported And Analysts Are Boosting Their Estimates - simplywall.st
Earnings Beat: Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts - uk.finance.yahoo.com
Aclaris Therapeutics Reports Q2 2025 Earnings, Highlights Clinical Advancements and Financial Metrics. - AInvest
Aclaris Therapeutics (ACRS) Reports Q2 Loss, Beats Revenue Estimates - MSN
Aclaris Therapeutics Reports Q2 2025 Results and Updates - TipRanks
Ati Inc. shares rise 2.39% premarket after Aclaris Therapeutics reported positive clinical results from Phase 2a trial of ITK/JAK3 inhibitor ATI-2138. - AInvest
Aclaris: Q2 Earnings Snapshot - The Washington Post
Aclaris Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Aclaris Therapeutics reports Q2 EPS (13c), consensus (13c) - TipRanks
Aclaris Therapeutics Inc earnings beat by $0.01, revenue topped estimates - Investing.com India
Aclaris Therapeutics shares rise 3.23% premarket after reporting Q2 earnings that met Wall Street expectations. - AInvest
Aclaris Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update - The Manila Times
What makes Aclaris Therapeutics Inc. stock price move sharplyFree Trade Scanner With Buy Zone Alerts - Newser
Leerink Partners Maintains Aclaris Therapeutics(ACRS.US) With Buy Rating, Maintains Target Price $7 - 富途牛牛
Relief Rally in Aclaris Therapeutics Inc. Stock — Can It HoldFree Membership Group - beatles.ru
What drives Aclaris Therapeutics Inc. stock priceMaximize your returns with smart trade entries - Jammu Links News
How many analysts rate Aclaris Therapeutics Inc. as a “Buy”Invest confidently with professional market insights - Jammu Links News
What are Aclaris Therapeutics Inc. company’s key revenue driversTriple-digit profit margins - Jammu Links News
Is Aclaris Therapeutics Inc. a growth stock or a value stockDiscover undervalued opportunities early - Jammu Links News
What is the dividend policy of Aclaris Therapeutics Inc. stockCapitalize on emerging market trends - Jammu Links News
Is Aclaris Therapeutics Inc. a good long term investmentCapitalize on market trends before they peak - Jammu Links News
What analysts say about Aclaris Therapeutics Inc. stockMarket-leading growth rates - Jammu Links News
What is the risk reward ratio of investing in Aclaris Therapeutics Inc. stockUnmatched profit potential - Jammu Links News
What are the latest earnings results for Aclaris Therapeutics Inc.Discover market opportunities with expert help - Jammu Links News
Wedbush Lowers Earnings Estimates for Aclaris Therapeutics - Defense World
What catalysts could drive Aclaris Therapeutics Inc. stock higher in 2025Unlock powerful market analysis and alerts - Jammu Links News
Aclaris Therapeutics Inc Stock (ACRS) Financials Data
Revenue
Net Income
Cash Flow
EPS
Aclaris Therapeutics Inc Stock (ACRS) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Mehra Anand | Director |
Nov 19 '24 |
Buy |
2.25 |
666,666 |
1,499,998 |
710,030 |
0.94%
1.72%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):